PepsiCo cuts earnings forecast as North American turnaround takes longer than expected
PepsiCo slashes its profit outlook as the North American revival stalls, sparking investor concern over cost pressures and a new GLP‑1 health trend.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
PepsiCo trimmed its full-year profit forecast and planned to cut costs as a lackluster performance and mounting costs in North America hurt its core profit forecast. While the company experienced strong overseas demand, the North American turnaround took longer than expected as the unit underperformed.
Following these third-quarter earnings developments, the story quieted without a definitive conclusion in the coverage regarding the long-term resolution of these pressures.
Epilogue added 38d ago, after coverage quieted.
The brief
PepsiCo announced on October 8, 2026 that it is lowering its full‑year earnings outlook after the third‑quarter results showed a slower‑than‑expected turnaround in its North American businesses. The company cited a lackluster performance in the United States and Canada, while noting that demand overseas remains strong. Coverage of the announcement highlights several themes.
Reuters frames the move as a timing issue for meeting targets set by activist investor Elliott Management and points to an emerging threat from GLP‑1 weight‑loss drugs that could curb sugary‑drink consumption. Bloomberg focuses on mounting cost pressures in North America that are eroding margins. CNBC’s headline stresses that the North American turnaround is taking longer than expected.
Yahoo Finance reports strong overseas demand but a weak domestic performance, while Quartz reports the cut to the full‑year profit forecast. Investors will watch the October 8 earnings call for details on how PepsiCo plans to address the cost headwinds and the GLP‑1 challenge, as well as any revised guidance for the remainder of the fiscal year. Subsequent reports from Reuters, Bloomberg and CNBC will be monitored for updates on cost‑management initiatives and progress on the North American turnaround.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (60% supported) Updated 40d ago.
Quick answers
What caused PepsiCo to lower its full‑year earnings forecast?
The company said a slower‑than‑expected turnaround in its North American operations and mounting cost pressures prompted the downgrade, while overseas demand stayed strong.
Which market segment is still showing strong demand according to the coverage?
Yahoo Finance and other outlets noted that overseas demand for PepsiCo products remains strong despite the domestic slowdown.
What external health trend is identified as a threat to PepsiCo’s beverage sales?
Reuters highlighted the rise of GLP‑1 weight‑loss drugs as an emerging threat that could reduce consumption of sugary drinks.
Coverage (11)
- PepsiCo sees strong overseas demand but a lackluster performance in North America for third quarter 10TV · 40d ago
- PepsiCo to cut costs as weak N.America business hurts core profit forecast Reuters · 40d ago
- PepsiCo Trims Outlook as North American Unit Underperforms WSJ · 40d ago
- Why is PepsiCo stock climbing today? By Investing.com Investing.com India · 40d ago
- PepsiCo sees strong overseas demand but a lackluster North American performance in the third quarter Yahoo Finance · 40d ago
- PepsiCo cuts full-year profit forecast in Q3 2026 earnings Quartz · 40d ago
- Ahead of PepsiCo Earnings, Here's What Barchart Data Says Comes Next for PEP Stock Barchart.com · 40d ago
- PepsiCo's Next Earnings Report on Oct. 8 2026 Could Send the Stock Plunging. Here's Why. Yahoo Finance · 40d ago
- PepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies Reuters · 40d ago
- PepsiCo Lowers Guidance on Mounting Costs in North America Bloomberg.com · 40d ago
- PepsiCo cuts earnings forecast as North American turnaround takes longer than expected CNBC · 40d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Hundreds of children in England prescribed weight-loss jabs, figures show
New figures reveal hundreds of children in England, including under-12s, have been prescribed weight-loss jabs.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.